GlassScriptPhysician profile
John A Huskins
NPI 1962460212
$4,796.55
in general payments reported to CMS, 2019-2025
40 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.12 · 2020: $167 · 2021: $401 · 2022: $846 · 2023: $1,148 · 2024: $994 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,299.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $789.22 | 2020-2025 | |
| Abbvie INC. | $554.71 | 2020-2025 | |
| Lilly USA, LLC | $546.83 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $501.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $342.07 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $269.31 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $222.45 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.93 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $108.95 | 2020-2025 | Veozah |
| Exeltis, USA INC. | $101.15 | 2021-2024 | Slynd |
| Dynavax Technologies Corporation | $91.81 | 2024-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $89.13 | 2023-2025 | Voquezna |
| Abbott Laboratories | $88.49 | 2022-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Exact Sciences Corporation | $75.52 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $71.21 | 2021-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Huskins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.